Abbott (NYSE: ABT) has released its first-quarter 2026 financial results, showcasing strong organic growth and the strategic integration of Exact Sciences into its world-leading diagnostics portfolio.
GSK has finalized its $950 million acquisition of 35Pharma Inc., securing HS235 a potential best-in-class treatment for pulmonary hypertension with unique metabolic benefits.
Johnson & Johnson delivers a robust start to the year with the Johnson & Johnson Q1 2026 Results, reporting $24.1 billion in revenue and increasing its full-year earnings guidance amid major clinical approvals.
Johnson & Johnson MedTech has announced the European launch of its latest pulsed field ablation innovation, VARIPULSE Pro, designed to enhance procedural efficiency and precision in treating cardiac arrhythmias.
Gilead Sciences has entered into a definitive agreement to acquire Tubulis for up to $5 billion, adding the “best-in-class” TUB-040 asset and a next-generation ADC platform to its growing oncology portfolio.
Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion, signaling a major expansion into the sleep medicine market through innovative orexin receptor agonists.
In a major industry shift, Hims & Hers will ditch compounded GLP-1s to offer branded Wegovy and Ozempic at self-pay prices following a settlement with Novo Nordisk.
GSK plc announced on March 3, 2026, the completion of its previously announced GSK RAPT Therapeutics acquisition for approximately $2.2 billion, bringing a California-based clinical-stage biopharmaceutical company specializing in novel therapies for inflammatory and immunologic diseases into its portfolio.
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has officially closed its acquisition of San Diego-based Avidity Biosciences, marking one of the most significant deals in the neuromuscular disease space in recent years. The transaction, originally announced on October 26, 2025, values Avidity at approximately $12 billion on a fully diluted basis, with an enterprise value of roughly $11 billion.
IQVIA Holdings Inc. announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. The acquisition includes five sites specializing in in vitro drug discovery services, supported by over 20 years of scientific data, creating an industry-leading integrated drug discovery platform.
